Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. (2022)
Attributed to:
saRNA SARS-CoV-2 vaccine
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.eclinm.2021.101262
PubMed Identifier: 35043093
Publication URI: http://europepmc.org/abstract/MED/35043093
Type: Journal Article/Review
Volume: 44
Parent Publication: EClinicalMedicine
ISSN: 2589-5370